Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

A Multicenter Phase II trial of TS-1/oxaliplatin (SOX) +bevacizumab in patients with unresectable advanced/metastatic colorectal cancer (HiSCO-02)

ABSTRACT: Interventions: Patients receive infusional oxaliplatin, bevacizumab, and oral TS-1 every 21 days. Primary outcome(s): Response rate Study Design: Single arm Non-randomized

DISEASE(S): Unresectable Advanced/metastatic Colorectal Cancer

PROVIDER: 2620419 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Json Xml

Similar Datasets

TS-seq

Project description:TS-seq

| PRJNA847608 | ENA

Gene expression analysis of ambient or 0.5% oxygen exposed rat trophoblast stem (TS) cells

Project description:Analysis of transcriptomic profile of TS cells grown in ambient (21% oxygen) and hypoxic (0.5% oxygen) conditions.

2016-12-07 | GSE80339 | GEO

Desulfobacula sp. TS strain:TS

Project description:Draft genome sequence of Desulfobacula sp. strain TS

| PRJNA175250 | ENA

Metabolic enhancement of developmental pausing (TS cells)

Project description:Embryonic stem (ES) cells and embryos reversibly pause via chemical mTOR inhibition. In this study, we investigate the tissue-specific response to mTORi-induced pausing in ES and trophoblast stem (TS) cells. To resolve the sequential rewiring of the proteome, we conducted a time-series proteomics experiment at 1, 3, 6, 12, 24, and 48 hours upon induction of pausing, and at 1, 3, 6, 12, 24, and 48 hours upon release of pausing in ES and TS cells. We find that ES, but not TS cells pause reversibly. To optimise developmental pausing conditions, we reasoned that by understanding the difference in pausing response of ES and TS cells, we could identify which pathways are essential for pausing. We found that KEGG pathways related to amino acid degradation, fatty acid degradation, and DNA repair are upregulated in ES cells, but downregulated in TS cells during entry into pausing. Moreover, by targeted metabolomics, we found a depletion of short chain carnitines in the paused ES cells. To extend the length of developmental pausing, we supplemented paused embryos with L-carnitine. The L-carnitine supplementation facilitates lipid usage and prolongs the pausing length by 19 days through the establishment of a more dormant state.

2023-11-06 | PXD033798 | Pride

RNA-seq Analyzes Transcriptomes of dnaB-Ts and dnaB-Ts ΔahpC at Both Permissive and Non-permissive Temperature

Project description:To generate a bona fide model to study post-stress baterial programmed cell death (PCD), we used a temperature-sensitive E. coli mutant (dnaB-Ts) since temperature stress can be rapidly reversed while other stress, such as antibotic treatment, is difficult to be rapidly and completely stopped and removed for post-stress PCD analysis. When cells were shifted from permissive (30 °C) to non-permissive temperature (42 °C), the dnaB-Ts ΔahpC double mutant maintained full surival while survival of the dnaB-Ts single mutant dropped 3 orders of magnitude; similarly, the double mutant showed much higher survival during treatments with quinolones and β-lactams at permissive temperature. The purpose of the RNA-seq analyses is to uncover molecular mechanisms underlying the increased survival of the dnaB-Ts ΔahpC double mutant by comparing its transcriptional profiles with that of the dnaB-Ts single mutant at both permissive and non-permissive temperature. The results showed that multiple antioxidative systems and stress response pathways were highly upregulated due to a deficiency of ahpC when combined with a dnaB-Ts mutation. The high expression of these genes are consistent with the lower levels of toxic reactive oxygen species (ROS) in the dnaB-Ts ΔahpC mutant than in the dnaB-Ts single mutant. Thus, the RNA-seq data supported that ROS are an important lethal factor in bacterial suicide pathways when bacterial cells are exposed to harsh stress.

2018-05-12 | GSE114262 | GEO

A phase II Study of Useful therapeutic strategy for metastatic Colorectal Cancer to Evaluate Oxaliplatin Stop and Go in SOX+Bmab

Project description:Interventions: TS-1 80mg/m2/day (day1-14) and Oxaliplatin 130mg/m2 (day1) and Bevacizumab 7.5mg/kg (day1) every 21 days for 4 courses followed by TS-1 80mg/m2/day (day1-14) and Bevacizumab 7.5mg/kg (day1) every 21 days for 8 courses. And next, administer until PD the same SOX+Bmab regimen. Primary outcome(s): Progression-free Survival Study Design: Single arm Non-randomized

| 2622829 | ecrin-mdr-crc

Massively parallel engineering of persistent CAR-Ts [XDRNA]

Project description:To evaluate the immunological landscape of PRDM1-crRNA CAR-Ts, we performed timecourse RNAseq. We also compared and contrasted transcription profiles of CAR-Ts mutated by two different PRDM1-crRNAs.

2022-12-09 | GSE207404 | GEO

Phase I study of XELOXIRI(CPT-11,L-OHP, capecitabine) with Bevacizumab in patients with unresectable advanced/metastatic colorectal cancer

Project description:Interventions: Patients receive infusional CPT-11,L-OHP, bevacizumab, and oral capecitabine every 21 days. Primary outcome(s): Safety Study Design: Single arm Non-randomized

| 2620878 | ecrin-mdr-crc

A multicenter randomized phase II/III trial of preoperative versus postoperative chemotherapy with XELOX plus bevacizumab in patients with resectable colorectal liver metastasis.

Project description:Interventions: A: Within 56 days after surgery, patients receive infusional oxaliplatin and oral capecitabine. Patients receive infusional bevacizumab as from second course. Treatment repeats every 21 days for 8 courses in the absence of disease progression or unacceptable toxicity. B: Patients receive infusional oxaliplatin, bevacizumab and oral capecitabine. Treatment repeats every 21 days for 8 courses in the absence of disease progression or unacceptable toxicity. Patients do not receive bevacizumab at last course. Within 56 days after chemotherapy, patients receive surgery. Primary outcome(s): Treatment compliance (phase II) Progression-free survival (phase III) Study Design: Parallel Randomized

| 2619239 | ecrin-mdr-crc

Paenibacillus alvei TS-15

Project description:Paenibacillus alvei TS-15 genome sequencing

| PRJNA77739 | ENA